TD Cowen Reaffirms Their Buy Rating on AstraZeneca (AZN)
TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...
AstraZeneca sees FY25 core EPS up low-double digit percentage
Sees FY25 revenue up high single-digit percentage. Sees FY25 tax rate 18%-22%. The company said, “The Company is unable to provide guidance on ...
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products. View on euronews ...